In addition to its internal technology development efforts, CO2 Solutions has formed synergistic external alliances to augment its commercialization program, including for enzyme optimization and production with Codexis, Inc., and process optimization and systems modeling with Procede Group BV.
Joint Development Agreement with Codexis, Inc.
Based in Redwood City, California, Codexis is a world leader in developing and manufacturing "super enzymes" to efficiently perform demanding industrial processes. Codexis' technology has been successfully commercialized for the low-cost, "green" manufacturing of a number of major pharmaceuticals such as Pfizer's LIPITOR®. Additionally, Codexis' technology has been validated in the clean energy sector through a multi-year collaboration with Shell to develop enzymes for producing advanced biofuels.
Through an exclusive Joint Development Agreement, Codexis is providing advanced carbonic anhydrase (CA) enzymes to CO2 Solutions, which will meet the demanding conditions of the carbon capture process.
To date, the program with Codexis has yielded impressive results in improving the stability of CA enzymes. This has allowed CO2 Solutions and Codexis to pursue pilot and demonstration opportunities for the technology and provides a strong pathway to commercial deployment.
Consulting and Technology Transfer Agreement with Procede Group BV
Based in The Netherlands, Procede Group is a leading developer of custom processes in the gas absorption field. Through an exclusive agreement with Procede Group, CO2 Solutions has access to its extensive carbon capture process expertise, which complements CO2 Solutions' internal development work on the enzymatic technology. This combined expertise provides a sound basis for process modeling, scale-up and validation of the technology in the power generation other key markets. CO2 Solutions is also pleased to have Dr. Geert Versteeg, the co-founder of Procede and an internationally respected expert in gas treating as a member of its Scientific Advisory Board.
Custom Immobilization Agreement with CLEA Technologies BV
Founded by Dr. Roger Sheldon, a respected authority in the field of biocatalysis, CLEA Technologies has commercialized an enzyme "bundling" process known as cross-linked enzyme-aggregates (CLEAs). The CLEA technology allows for the efficient utilization of enzymes in industrial processes by both improving stability as well as reusability. Through an exclusive agreement signed in 2010, CLEA Technologies is developing carbonic anhydrase CLEAs for CO2 Solutions' carbon capture process. As part of this agreement, CO2 Solutions also obtained worldwide exclusive market rights to the CLEA technology for cabon capture applications.